The Swiss pharma major Novartis AG has filed a special leave petition with the Supreme Court of India against the of Intellectual Property Appellate Board (IPAB) decision to reject the company's plea for patenting its imatinib mesylate - the blood cancer drug Glivec - in the country.
The details can be read here.
No comments:
Post a Comment